BofA/Merrill Lynch Upgrades Acadia Pharmaceuticals (ACAD) to Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to BofA/Merrill Lynch Upgrades Acadia Pharmaceuticals (ACAD) to Buy

ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results

November 7, 2016 4:05 PM EST

NUPLAZID® Net Product Sales Grew to $5.3 Million in the First Full Quarter of Commercialization

Expanding Pimavanserin Clinical Program With Initiation of Studies for Alzheimers Disease Agitation and Adjunctive Treatment of Schizophrenia

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its unaudited financial results for the third quarter ended September 30, 2016.

We are very pleased with the launch... More